Summary of Health Care Provisions in Energy & Commerce Reconciliation Bill
Brownstein Client Alert, September 17, 2021
This week, the House Energy and Commerce Committee approved sweeping health care legislation as part of the Democratic Congress’ plan to enact a $3.5 trillion legislative package through budget reconciliation. The committee considered six subtitles that contained health-related legislation: Drug Pricing, Affordable Care Act, Medicaid, CHIP, Medicare and Public Health . Notably, the committee did not approve the proposed drug pricing plan, which would allow for negotiation of drug prices in Medicare Part D, with three Democrats voting in opposition. This puts a signature piece of the Democrats’ proposal, which would save close to $500 billion to pay for other priorities, in peril.
The Energy and Commerce Committee legislation proposes to spend $190 billion for Home- and Community-Based Services (HCBS), closing the Medicaid gap (no known score, estimated to be ~$300 billion), and $300 billion to expand Medicare benefits to include vision, dental and hearing. In order to offset this spending, they propose fully repealing the rebate rule, which will raise about $170 billion as well as prescription drug reforms that would save approximately $500 billion. While the Energy & Commerce Committee voted the drug provisions down, the House Ways and Means Committee adopted legislative recommendations containing identical language for drug pricing. This gives the drug provisions a path forward in the process, though it may not have enough support to ultimately pass the House. None of the costs or savings of the programs are official yet; the Congressional Budget Office will publish their estimates in upcoming weeks.
The legislative recommendations approved by the Energy and Commerce Committee will be combined with the recommendations from the other House committees by the House Budget Committee. Following a markup by the House Budget Committee, the combined legislation will be transmitted to the House Rules Committee where it will receive its own hearing. During this hearing, amendments can be introduced or made to adjust the bill. It is anticipated that the drug pricing language will be renegotiated over the coming weeks. House Democrats will need the savings generated from these provisions in order to pay for their other health care priorities included in the reconciliation bill.
Click here for the full summary and analysis.
Recent Insights
Read MoreFCC Extends Compliance Deadline for “Revoke All” Rule
Client Alert | January 07, 2026China Strengthens Export Controls on Dual-Use Items to Japan
Client Alert | January 06, 20262026 Colorado Legislative Session Preview
Client Alert | January 06, 2026The Implications of U.S. Action in Venezuela on the Energy and Critical Minerals Sector
Client Alert | January 05, 2026GAO Releases Report on the Importance of Federal Home Loan Banks
Client Alert | January 05, 2026FDA Proposes Incentives for Domestic Drug Development in PDUFA Negotiations
You have chosen to send an email to Brownstein Hyatt Farber Schreck or one of its lawyers. The sending and receipt of this email and the information in it does not in itself create and attorney-client relationship between us.
If you are not already a client, you should not provide us with information that you wish to have treated as privileged or confidential without first speaking to one of our lawyers.
If you provide information before we confirm that you are a client and that we are willing and able to represent you, we may not be required to treat that information as privileged, confidential, or protected information, and we may be able to represent a party adverse to you and even to use the information you submit to us against you.
I have read this and want to send an email.